Business
Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics
CAMBRIDGE, Mass., October 14, 2025--Nabla Bio, a biotechnology company pioneering de novo therapeutics design with generative AI, today announced a new, multi-year research collaboration with Takeda.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3200,"height":406,"url":"https://media.zenfs.com/en/business-wire.com/773e4905780f7e7968844d46856e4271"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dR9Z7exogvpjY6lP7jetAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/773e4905780f7e7968844d46856e4271","width":960,"height":122},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ZBfxm8eAHlmzuEh8LsGYXA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMDQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/773e4905780f7e7968844d46856e4271","width":1200,"height":152}},"lazy":false},{"type":"text","content":"Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"Multi-year partnership deploys Nabla Bio’s AI design and human-relevant wet-lab capabilities broadly across Takeda’s early-stage development programs","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"New collaboration builds on success of first engagement as well as step-change improvements to Nabla Bio’s JAM foundation model","length":127,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., October 14, 2025--(BUSINESS WIRE)--Nabla Bio, a biotechnology company pioneering de novo therapeutics design with generative AI, today announced a new, multi-year research collaboration with Takeda.","length":216,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Nabla Bio will receive double-digit millions in upfront and research cost payments and is eligible to receive success-based payments that may exceed $1 billion in total.","length":203,"tagName":"p"},{"type":"text","content":"This second collaboration will deploy Nabla Bio’s proprietary biomolecular design platform, Joint Atomic Model (JAM), across Takeda’s early-stage development programs. This new collaboration will include, but is not limited to, de novo design of antibodies in parallel for multiple targets, multispecifics, challenging targets, and other custom therapeutics.","length":358,"tagName":"p"},{"type":"text","content":""Since 2022, we’ve collaborated with Takeda...